IOVA250117P17500
- 8.30
- 0.000.00%
Iovance Biotherapeutics Newsroom
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $22
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
Iovance Biotherapeutics (IOVA) Gets a Buy From Truist Financial
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
JMP Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $21 to $32
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $25
Iovance Biotherapeutics Analyst Ratings
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Promising Efficacy and Long-term Response of Iovance Biotherapeutics' Lifileucel in NSCLC: A Buy Recommendation
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Analyst Ratings